|WE GO DEEP TO FORMULATE SCIENCE STORIES THAT INSPIRE STAKEHOLDERS AND DRIVE VALUE.|
We partner with leaders in life sciences and biotechnology to create and implement communication strategies that tell each client’s unique story for maximum impact with target audiences.
Our team is defined by two key attributes. We are highly experienced in the specialized field of life sciences, and we care about delivering results for our clients. We apply our skills to successfully translate science into compelling language and memorable visuals to portray the possibilities of your innovation for patients.
At the Yates Network, we apply the lens of the outside world to develop a sharp strategy at the center of every communications program. Our approach is grounded in a strong and differentiated market positioning as the foundation for driving momentum and creating value. Then, we implement creative tools and visibility programs that amplify compelling science and build industry leadership.
We work closely with a select group of clients – bringing our rigor and enthusiasm for delivering results.
We live and breathe strategy. In the biotech and life sciences industry, we recognize that a strong and distinct positioning that provides clear differentiation is the foundation for communicating value to stakeholders.
We unlock your story’s power with expert and creative content. Crafting a robust science and innovation story that sets you apart and clearly communicates your potential and vision extends throughout all communications—from news milestones to thought leadership articles, and from websites to scientific visuals.
We embrace the opportunities for story proliferation. We activate today’s dynamic and multi-faceted communication environment that includes traditional, digital and social media, with a planning process designed to have impact on your stakeholders.
Barbara Yates established The Yates Network in 2000 with the aim to establish a consultancy to bring strategic communications ideas, media visibility, and passion to biotech companies who possess the science and people to make a major impact for patients. Barbara has more than 25 years of communications experience in roles as an internal corporate communications leader and as an external consultant – but, always with high-growth and start-up companies.
Barbara offers biotech clients a broad range of expertise and a vast professional network from her work in communications to the media, investors, regulators, physicians, and patient advocacy groups. She brings to a project team the unique ability to develop or enhance a strategy, and then fully integrate it with high-impact tactics and programs that achieve business results.
In her decades as a consultant, Barbara has worked for a wide range of clients from biotech companies, both private and public, as well as big pharma companies, like Pfizer and Astra Zeneca. Clients view her as a trusted advisor and team leader in ‘game changing’ scientific and business news, such as journal publications in Nature, JAMA, and NEJM; major partnering deals; and IPOs. Her experience spans most all therapeutic areas including oncology, CV, mental illness, neurological diseases, HIV/AIDs, infectious disease, endocrinology/metabolic disease, diabetes, inflammation, and rare disorders.
Prior to founding The Yates Network, Barbara served as Vice President of corporate communications in the US for Serono, Inc., as it emerged to become a major biotech company with multiple blockbusters and more than $1 billion in global product sales. With responsibility for Serono’s US public relations in all therapeutic areas, including multiple sclerosis, reproductive health, and HIV/AIDS, Barbara managed programs for media relations, patient advocacy relations, medical meetings and publications, and clinical trial communications.
Barbara has a BA from Cornell University. She earned a Masters of Business Administration (MBA) and Masters of Public Health (MPH) from Boston University.
Gina is a communications professional with more than 25 years experience in the development of strategic communications programs within the biotechnology industry. Specific skill sets include corporate communications, investor relations, marketing communications, public relations, advocacy and community relations.
Gina has developed and implemented broad communications programs across a variety of key audiences, supported the launch of five breakthrough biotechnology products and counseled senior management and managed communications issues around significant strategic shifts.
Gina has held senior roles within both early-stage and established biotechnology companies including Senior Director of Investor Relations and Corporate Communications at Millennium Pharmaceuticals, Vice President of Corporate Communications for CombinatoRx and various communications roles at Wyeth Research.
She earned an M.S. in Communications Management from Simmons College and a B.A. in Marketing Management from Northeastern University. Gina is an active member of the Healthcare Business Women’s Association, the National Investor Relations Institute and the Massachusetts Biotechnology Council.
Jennifer has over fifteen years of biotech and start-up experience. She completed a BS with honors at UC Berkeley and a PhD at MIT in chemical engineering with a focus on biomedical engineering. Following her PhD, Jennifer spent three years at the Boston Consulting Group working primarily in the healthcare practice area. She then worked with David Edwards at Harvard University and Medicine in Need, a start-up working to apply drug delivery solutions to improve treatment of endemic diseases of the developing world. Jennifer was a co-Founder of Sirtis Pharmaceuticals, working in business and corporate development. Following three years in business development at Vertex Pharmaceuticals, she co-Founded Civitas Therapeutics. Jennifer now consults for small and emerging biotech companies and works with The Yates Network.
Kathryn Morris has more than 25 years of agency and corporate public relations experience. She has helped biotech companies reach their target audiences by connecting with reporters, building relationships with key publications and working the phones and e-mail to pitch news.
Kathryn’s media strategy and pitching projects have helped launch products and position companies for a multitude of high-visibility biotech clients. Kathryn has played a leadership role in the media outreach plans and placement for biotech and health care firms that include Alnylam, Momenta, Alkermes, Sirtris, Ortho McNeil, Novartis, National Women’s Health Resource Center, Amgen, Janssen, Serono, and Celgene.
The hallmark of Kathryn’s professional expertise is her strong rapport with media of all types, from the newswires and newsweeklies, to national newspapers, business publications, morning shows, news programs, and a variety of online media.
Earlier in her career, Kathryn built her base of media relations experience as a PR professional with Burson-Marsteller. Kathryn earned a bachelor of journalism degree from the University of Missouri, cum laude.
Mary Moynihan applies more than 25 years of focused work in bioscience communications, journalism, and publication and graphic design to provide strategy, text and graphic content development, and website development expertise to clients of The Yates Network.
Mary has extensive experience working closely with biotech entrepreneurs and understands the unique challenges science-based startups face in developing corporate positioning and value propositions for products with long development timelines; keeping pace with shifting regulations on drug research; maximizing yield from limited resources; and winning the support of business, investor, and scientific audiences.
Mary’s past experience includes service as a PR/communications consultant to dozens of biotechnology companies and select research institutions. Prior to that, she was founding director of communications for the University of Maryland Biotechnology Institute, where she led public relations for the institute’s mission to advance basic research while partnering with industry to apply research in the areas of new drug development, protein engineering, agricultural biotechnology, and marine biotechnology. Earlier in her career, Mary served in corporate communications positions as well as editing positions at national and regional publications, developing expertise in communications strategy, positioning and message development, the practice of media relations from “both sides of the desk,” graphic design and typography, publication design and production, state legislative communications, and speechwriting.
Anne Tsimboukis has more than 20 years of experience as a designer, and has spent the majority of her career working with biotech companies to develop, launch and maintain brands. For the past ten years, Anne has worked with The Yates Network on a range of design projects, including websites, Powerpoint presentations and other materials.
Anne is uniquely qualified in understanding how to convey complex and sophisticated scientific concepts in designs that bring to life the stories of emerging biotech companies. Previously, Anne worked as an in-house designer for Millennium Pharmaceuticals where she played a lead role in the design for the corporate identify and visual communications materials during the exciting years of the genomics revolution, major partnering deals, and first product launch for Millennium. Anne earned a Bachelor of Fine Arts in Photography from Cleveland Institute of Art.
|Alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as RNA interference, or RNAi.|
|Baxalta is developing new treatments for people with rare diseases and underserved conditions with a focus on hematology, immunology, and oncology.|
|Emulate is using its Organs-on-Chips technology to create living products for understanding how diseases, medicines, chemicals, and foods affect human health.|
|WuXi NextCODE is a sequence-based clinical diagnostics company delivering a powerful solution to genome interpretation and big data challenges.|
|Concert Pharmaceuticals uses deuterium-based chemistry to create and develop highly differentiated new medicines by leveraging decades of pharmaceutical and clinical experience to reduce time, risk, and expense.|
|True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need.|
|X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and reverse immune suppression to treat cancer and rare diseases of the immune system.|
|XTuit is developing novel microenvironment-targeted therapeutics that act to silence activated stromal cells, turning off multiple pathogenic signaling pathways that drive disease in fibrosis and cancer.|
|Arrakis Therapeutics is pioneering the discovery of a new class of medicines that directly target RNA, using proprietary platforms to identify new RNA targets and small molecule drugs for a range of diseases.|
|Navitor is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling via the mTORC1 pathway.|
|Ribon Therapeutics is pioneering the discovery of new cancer medicines that target monoPARP proteins, critical regulators of cancer survival mechanisms.|
|Scholar Rock is discovering and developing a new class of biologic therapies that target disease-causing proteins in the microenvironment, resulting in therapeutic effects specifically at the source of disease.|
To discuss how The Yates Network can support your communications needs with strategic, high-impact results, please call us or email us: